Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Empasiprubart - argenx/Broteio Pharma

Next Previous
Drug Profile

Empasiprubart - argenx/Broteio Pharma

Alternative Names: ARGX-117

Latest Information Update: 19 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator argenx; Broteio Pharma
  • Developer argenx
  • Class Anti-inflammatories; Antianaemics; Antibodies; Antivirals; Monoclonal antibodies
  • Mechanism of Action Complement C2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multifocal motor neuropathy
  • Phase II Delayed graft function; Dermatomyositis
  • No development reported Kidney disorders; Motor neuron disease
  • Discontinued COVID 2019 infections

Most Recent Events

  • 08 May 2025 argenx plans a phase III EMVIGORATE trial for Chronic inflammatory demyelinating polyradiculoneuropathy in unknown location (IV, Infusion) in the first half of 2025 (NCT06920004)
  • 18 Dec 2024 Phase-III clinical trials in Multifocal motor neuropathy in USA (IV) (NCT06742190)
  • 04 Nov 2024 argenx completes a phase II trial in Multifocal motor neuropathy in Austria, Belgium, France, Italy, Netherlands, Poland, Spain, United Kingdom, Canada, Germany and the the US (IV) (NCT05225675)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top